N.N. Petrov National Medical Research Center of Oncology
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Walter, Harriet
NCT03568656 / 2018-000285-10: Study to Evaluate CCS1477 in Advanced Tumours

Active, not recruiting
1/2
350
Europe, US
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
CellCentric Ltd.
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
08/25
08/25
Keynote-D20, NCT04752826 / 2020-002090-10: BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies

Recruiting
1/2
176
Europe, US, RoW
BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
BioInvent International AB, Merck Sharp & Dohme LLC
Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
12/26
01/28
CCS1477-02, NCT04068597 / 2019-000104-15: Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Recruiting
1/2
250
Europe, US
CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax
CellCentric Ltd.
Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
03/27
03/27
FIH, NCT04104776 / 2020-004952-14: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
275
Europe, US, RoW
Tulmimetostat, DZR123, Enzalutamide
Novartis Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
02/30
02/30
Lim, Sean
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
Keynote-D20, NCT04752826 / 2020-002090-10: BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies

Recruiting
1/2
176
Europe, US, RoW
BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
BioInvent International AB, Merck Sharp & Dohme LLC
Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
12/26
01/28
Levchenko, Evgeny
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
152
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/26
05/28
NCT06842966: Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Recruiting
2
300
RoW
4-MUST, trimebutine 4-methylumbelliferyl sulfate, Placebo
Valenta Pharm JSC
Chronic Cholecystitis, Biliary Dyskinesia
12/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Walter, Harriet
NCT03568656 / 2018-000285-10: Study to Evaluate CCS1477 in Advanced Tumours

Active, not recruiting
1/2
350
Europe, US
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
CellCentric Ltd.
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
08/25
08/25
Keynote-D20, NCT04752826 / 2020-002090-10: BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies

Recruiting
1/2
176
Europe, US, RoW
BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
BioInvent International AB, Merck Sharp & Dohme LLC
Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
12/26
01/28
CCS1477-02, NCT04068597 / 2019-000104-15: Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Recruiting
1/2
250
Europe, US
CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax
CellCentric Ltd.
Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
03/27
03/27
FIH, NCT04104776 / 2020-004952-14: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
275
Europe, US, RoW
Tulmimetostat, DZR123, Enzalutamide
Novartis Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
02/30
02/30
Lim, Sean
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
Keynote-D20, NCT04752826 / 2020-002090-10: BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies

Recruiting
1/2
176
Europe, US, RoW
BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
BioInvent International AB, Merck Sharp & Dohme LLC
Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
12/26
01/28
Levchenko, Evgeny
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
152
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/26
05/28
NCT06842966: Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Recruiting
2
300
RoW
4-MUST, trimebutine 4-methylumbelliferyl sulfate, Placebo
Valenta Pharm JSC
Chronic Cholecystitis, Biliary Dyskinesia
12/26
12/26

Download Options